![]() The acquisition is expected to close in January 2021 following customary approval requirements. The OSSIX portfolio will be the foundation of Dentsply Sirona’s regenerative portfolio. It is now promoting the full OSSIX portfolio in the United States, Canada, Columbia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey, and Hong Kong.Ĭlinicians will benefit from the implementation of OSSIX products in a broad set of solutions and workflows and from Dentsply Sirona’s capacity to invest in future development, the company said. “Our R&D pipeline will continue to develop new, safe, and transformational solutions that simplify procedures and overcome major deficiencies in existing biomaterial-based regenerative products,” said Itzhaky.ĭentsply Sirona has had distribution agreements with Datum Dental since 2016. Dentsply Sirona offers us opportunities to work on continued innovation with the strongest R&D team in the industry,” said Itay Itzhaky, chief executive officer of Datum Dental. “We are pleased that the OSSIX family is becoming part of the market leader in dental. ![]() “The acquisition is another important step for us to deliver on our purpose to empower dental professionals to provide patients with better dental care and make people smile,” said Dorff. The biomaterial sector is an important cornerstone of the future of dentistry,” said Gene Dorff, vice president of the implants product group at Dentsply Sirona. “Datum Dental perfectly fits in our strategy to deliver innovative and meaningful solutions for our customers. Driven by the GLYMATRIX core technology, Dentsply Sirona said, OSSIX’s bio-durable design will ensure long-term predictable and superior results. The acquisition, then, will open up significant opportunities within Dentsply Sirona’s implants segment, the company said. In addition, Dentsply Sirona noted many promising products in Datum Dental’s strong R&D pipeline. Also, Datum Dental is known for its dental regeneration products and its GLYMATRIX proprietary technology, Dentsply Sirona said.ĭatum Dental complements Dentsply Sirona’s existing implant dentistry strategy around Ankylos, Astra Tech Implant System, Xive, and Atlantis, Dentsply Sirona said. Ossix Volumax is currently available in 4 sizes, ranging from 10 x 12.5 mm to 30 X 40 mm.Dentsply Sirona has acquired Datum Dental, which produces the OSSIX line of biomaterials. Ossix Volumax is pending the CE mark, Health Canada license and MOH Israel certificate. Ossix Volumax is currently available in the USA (via OraPharma) and Korea (via Purgo Biologics). We will continue to develop products featuring this unique technology, for the benefit of patients and healthcare around the globe.” Over 100 publications have been published to date. This proprietary technology uses sugars to cross-link collagen molecules, producing a collagen matrix which can be bio-programmed and tailored to deliver a range of products of varying physical properties, customized longevity and controlled rates of degradation. Itay Itzhaky, Chairman at Datum Dental said “The new Ossix Volumax and the well-known and decade-long proven Ossix Plus both feature Glymatrix. I foresee that clinicians may choose Ossix Volumax for use in the esthetic zone as well, especially for masking implants.” “In implant surgery procedures where there is missing buccal bone, residual dehiscence or buccal dehiscence, this new thick collagen matrix is expected to restore volume. Zubery believes that Ossix Volumax has significant potential to restore lost volume in guided bone regeneration (GBR), guided tissue regeneration (GTR) and soft tissue augmentation cases. Zubery will also be delivering an oral presentation at the European Association of Osseointegration (EAO) to be held later this month in Paris.ĭr. Yuval Zubery, D.M.D., specialist in periodontics and Chief Medical Officer at Datum Dental, led the study and presented the findings during the poster session. The results also show Ossix Volumax’ mineralization and ossification progress. It is the newest addition to the Ossix line of dental regeneration products for use in periodontics, oral surgery, dental implantology and dental aesthetic procedures.ĭata presented at the American Association of Periodontology (AAP) Annual Meeting Research Forum Poster Session, clearly demonstrates statistically significant improved bone growth using Ossix Volumax vs. ![]() 2 mm), resorbable collagen scaffold in the USA. Tuesday, September 13, 2016, 12:00 Hrs ĭatum Dental, a subsidiary of Datum Biotech, announced that Ossix Volumax has received FDA 510(k) clearance, enabling the company to commercially market this new volumizing (approx. Click hereĭatum Dental receives US FDA clearance to market Ossix Volumax, new collagen scaffold for GBR and GTR You can get e-magazine links on WhatsApp.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |